Clinical observation of docetaxel combined with carboplatin as second -or third -line treatment for patients ;with advanced triple -negative breast cancer
10.3760/cma.j.issn.1008-6706.2015.21.003
- VernacularTitle:多西他赛联合卡铂二、三线治疗晚期三阴乳腺癌临床观察
- Author:
Qinghua LIU
;
Mingying ZHANG
;
Chunjuan LIU
;
Wenjun YU
;
Chuantao ZHANG
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Docetaxel;
Carboplatin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2015;(21):3207-3210
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and adverse reactions of docetaxel and carboplatin 21 day regimen (TC)as second -or third -line in treatment of patients with advanced triple -negative breast cancer (ATNBC).Methods 37 ATNBC patients with anthracyclines resistance were given docetaxel 70mg/m2 ,the first day of intravenous drip,carboplatin AUC =5,through intravenous drip on the first day,21 days for a course of treatment, until disease progression or not tolerated or most received six cycles of chemotherapy.Results 147 cycles of chemo-therapy were completed in 37 patients,and the median chemotherapy cycle was 4 cycles.The efficacy and adverse reactions could be evaluated in all patients.Among them,complete remission (CR)in 0 patient,partial remission (PR)in 12 patients (32.43%),stable (SD)in 11 patients (29.73%),and progression (PD)in 14 patients (41.18%).The effective rate(CR +PR)was 32.43%.The disease control rate (CR +PR +SD)was 62.15%,median TTP was 3.9 months (95%CI:4 -8months),and median OS was 10 months.Until the end of follow -up,there were 3 patients with no progress.The main adverse reactions were hematological toxicity (51.53%)and gastrointestinal reaction (56.76%).Conclusion TC regimen is effective and safe in the treatment of patients with ATNBC.
